About PathogenDX
PathogenDX is a Healthcare company based in Tucson (United States) founded in 2014 by Eric Lachance and Michael Hogan. Provider of DNA-based pathogen testing kits. PathogenDX has raised $11.58 million across 5 funding rounds from investors including NIH, HHS and Entourage Effect Capital. The company has 31 employees. PathogenDX offers products and services including D3 Arrayâ„¢, Octaâ„¢ AutoPrep Station, and Sero X Assay. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Assays and Drug Discovery. Its legal entity is Pathogendx, Inc. Its competitors include Inflammatix, Agendia and GenomeDx Biosciences; 3 of its 3 listed competitors have raised funding.
Company details
PathogenDX was founded in 2014 and is based in Tucson, United States. DNA-based testing kits for pathogen detection are offered by the company to the botanicals, food, and agriculture industries. Operations center on microbial testing services, including those for cannabis and botanical applications, with a focus on supporting safety and quality assessments in these sectors.
- Headquarters Tucson, United States
- Employees 31
- Founders Eric Lachance, Michael Hogan
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website pathogendx.com
- Social LinkedIn X Facebook Instagram
- Legal Name Pathogendx, Inc
- Total Equity Funding$11.58M (USD)
in 5 rounds
- InvestorsNIH
& 7 more
- Employee Count31
Products & Services of PathogenDX
PathogenDX offers a comprehensive portfolio of products and services, including D3 Array™, Octa™ AutoPrep Station, and Sero X Assay.
Rapid multiplexed pathogen detection for clinical and food use
Automates lab workflows for cannabis pathogen testing
Detects Salmonella serotypes in food processing
Funding Insights of PathogenDX
PathogenDX has successfully raised a total of $11.58M across 5 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $11.58M
- Total Rounds 5
- First Round $675,000
(Apr 2016)
- Investors Count 8
All 5 funding rounds of PathogenDX with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2020 | Grant | – | – | ||
| Aug 2020 | $1.08M | Grant | – | – | |
| Sep 2019 | $7.5M | Series B | – | Entourage Effect Capital | |
| Jul 2018 | $3.4M | Series A | – | – | |
| Apr 2016 | $675,000 | Seed | – | – | – |
8 investors in total: 8 institutional.
Investors in PathogenDX
PathogenDX has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, HHS and Entourage Effect Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment firm focused on cannabis industry growth and leadership. | 2014 | entourageeffectcapital.com | ||
Investments are focused on the emerging global cannabis industry. | altitudein.com | |||
| arcadianpartnersllc.org | ||||
Capital and operational resources are provided to growing companies. | 2018 | flatironventurepartners.com | New York, United States | |
Salveo Capital is focused on funding cannabis industry ventures. | 2018 | salveocapital.com | Northbrook, United States | |
| canopy.vc | ||||
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for PathogenDX
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of PathogenDX
17 people are tracked at PathogenDX (6 in leadership, 9 in board & advisors, 2 in team); the tracked headcount is 31.
| Name | Role | Group |
|---|---|---|
Eric Lachance | Co-Founder & COO | Leadership |
Michael Hogan | Co-Founder & CSO | Leadership |
David Stolberg | Creative Director & Founder, RULE OF 3, Marketing Team | Leadership |
Milan Patel | Co-Founder & CEO | Leadership |
Benjamin Katchman | Vice President Of Product Development | Leadership |
Jeff Ryskamp | CFO | Leadership |
Sue Evans | Board Advisor, Clinical & Human Diagnostics | Board & advisors |
Neal Patel | Board Member | Board & advisors |
Paul Glyer | Board Advisor, Clinical & Human Diagnostics | Board & advisors |
Michael Dovbish | Board Advisor | Board & advisors |
David Acheson | Board Advisor, Chairman of the Food Safety Committee | Board & advisors |
Jon Vaught | Board Advisor | Board & advisors |
Jon Trauben | Board Member | Board & advisors |
Ephraim Lindenbaum | Board Member | Board & advisors |
Reggie Gaudino | Board Advisor | Board & advisors |
Joy Prisco | Senior Scientist | Team |
Janisha Damania | Controller | Team |
Complete people profiles for PathogenDX
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of PathogenDX
3 dated milestones of PathogenDX across 6 years, from founding to its latest funding, stage changes and deals.
- Founded PathogenDX is founded.
- Funding First funding round of $675K.
- Funding Latest funding round, Grant,.
Competitors of PathogenDX
PathogenDX has 3 listed competitors in our database, 3 of them funded. They include Inflammatix, Agendia and GenomeDx Biosciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| inflammatix.com | 2016 | San Francisco, United States | $191.47M | 54 | Provider of diagnostic solutions for systemic infections | |
| agendia.com | 2003 | Irvine, United States | $123M | 203 | Genomic diagnostic products for cancer treatment are provided. | |
| genomedx.com | 2008 | San Diego, United States | $69.75M | 159 | Genomic tests for urologic cancers are developed and commercialized. |
Detailed competitors of PathogenDX
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of PathogenDX
The website of PathogenDX (pathogendx.com) receives about 1K visits a month.
- Monthly visits1K
▼ 50.1% vs previous month
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as PathogenDX (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Pathogendx
Complete news archive for PathogenDX
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about PathogenDX
PathogenDX was founded in 2014 and raised its 1st funding round 2 years after it was founded.
PathogenDX is headquartered in Tucson, United States. It is registered at Tucson, Arizona, United States.
PathogenDX is a funded company, having raised a total of $11.58M across 5 funding rounds to date. The company's 1st funding round was a Seed of $675K, raised on Apr 2016.
PathogenDX has 31 employees.
PathogenDX was founded in 2014 and is based in Tucson, United States. DNA-based testing kits for pathogen detection are offered by the company to the botanicals, food, and agriculture industries. Operations center on microbial testing services, including those for cannabis and botanical applications, with a focus on supporting safety and quality assessments in these sectors.
PathogenDX's top competitors include Inflammatix, Agendia and GenomeDx Biosciences.
PathogenDX offers D3 Arrayâ„¢, Octaâ„¢ AutoPrep Station, and Sero X Assay.
PathogenDX has 8 investors. Key investors include NIH, HHS, Entourage Effect Capital, Altitude Investment Management, and Arcadian Investment Partners.
PathogenDX operates through Pathogendx, Inc.